Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference




Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 12:35 p.m. ET.

A webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Contacts

Aron Feingold

Investor and Media Relations

investor@geron.com
media@geron.com